{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:42:12Z","timestamp":1777390932296,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.amjcard.2017.12.009","type":"journal-article","created":{"date-parts":[[2017,12,25]],"date-time":"2017-12-25T10:04:03Z","timestamp":1514196243000},"page":"768-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Platelet Function Analyzer 100 and Brain Natriuretic Peptide as Biomarkers in Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"121","author":[{"given":"Joseph L.","family":"Blackshear","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Safford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Martijn","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve R.","family":"Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian P.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen S.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.12.009_bib0010","doi-asserted-by":"crossref","first-page":"e2701","DOI":"10.1016\/j.jacc.2011.06.011","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/ American Heart Association Task Force on Practice Guidelines","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM199308053290614","article-title":"Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy","volume":"329","author":"Yoshibayashi","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.CIR.88.2.372","article-title":"Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy","volume":"88","author":"Hasegawa","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0025","first-page":"550","article-title":"Screening for familial hypertrophic cardiomyopathy using brain natriuretic peptide","volume":"20","author":"Khan","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0030","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.CIR.0000117098.75727.D8","article-title":"Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy","volume":"109","author":"Maron","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0035","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ahj.2005.02.045","article-title":"Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy","volume":"150","author":"Arteaga","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0040","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1253\/circj.69.951","article-title":"Functional assessment by myocardial performance index (Tei Index) correlates with plasma brain natriuretic peptide concentration in patients with hypertrophic cardiomyopathy","volume":"69","author":"Okawa","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0045","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2006.06.053","article-title":"Usefulness of N-terminal Pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy","volume":"98","author":"Mutlu","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2006.02.057","article-title":"Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy","volume":"98","author":"Thaman","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cardfail.2007.01.011","article-title":"Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy","volume":"13","author":"Pieroni","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0060","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.amjcard.2007.11.071","article-title":"Significance of plasma levels of N-terminal pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the \u03b1-tropomyosin gene","volume":"101","author":"Magga","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1742-1241.2009.02184.x","article-title":"Brain natriuretic peptide and the athlete's heart: a pilot study","volume":"64","author":"Pagourelias","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0070","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1939-1676.2011.00776.x","article-title":"Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats","volume":"25","author":"Fox","year":"2011","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cardfail.2012.04.005","article-title":"Plasma pro-B-type natriuretic peptide testing as a screening method of hypertrophic cardiomyopathy","volume":"18","author":"Fernandes","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0080","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/CIRCULATIONAHA.108.786681","article-title":"Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction","volume":"118","author":"Le Tourneau","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4065\/mcp.2010.0309","article-title":"Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy","volume":"86","author":"Blackshear","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.amjcard.2012.10.015","article-title":"Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] Study)","volume":"111","author":"Blackshear","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/MBC.0b013e32832da1ad","article-title":"Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease","volume":"20","author":"Favaloro","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0105","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/eurheartj\/ehl137","article-title":"Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes","volume":"27","author":"Pellicia","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0110","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/eurheartj\/ehi108","article-title":"Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol","volume":"26","author":"Corrado","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2261-13-70","article-title":"Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study","volume":"13","author":"McGorrian","year":"2013","journal-title":"BMC Cardiovasc Disor"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0120","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.amjcard.2015.11.016","article-title":"Usefulness of Von Willebrand factor activity indexes to predict therapeutic response in hypertrophic cardiomyopathy","volume":"117","author":"Blackshear","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0130","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00277-011-1266-4","article-title":"Von Willebrand disease: a clinical and laboratory study of 65 patients","volume":"90","author":"Chen","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0135","first-page":"1203","article-title":"High resolution multimer analysis and the PFA-100 platelet function analyzer can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level","volume":"58","author":"Weiss","year":"2012","journal-title":"Clin Lab"},{"key":"10.1016\/j.amjcard.2017.12.009_bib0140","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cardfail.2010.07.245","article-title":"Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy","volume":"16","author":"Moreno","year":"2010","journal-title":"J Card Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917319240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917319240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T22:55:49Z","timestamp":1535151349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917319240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0002914917319240"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.12.009","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet Function Analyzer 100 and Brain Natriuretic Peptide as Biomarkers in Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}